CHU Bordeaux
CHU Bordeaux
Bordeaux, France2 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| AVAJAK: Apixaban/Rivaroxaban Versus Aspirin for Primary Prevention of Thrombo-embolic Complications in JAK2V617F-positive Myeloproliferative Neoplasms | Embolism and Thrombosis, Hemic and Lymphatic Diseases, Hemorrhage, Myeloproliferative Disorders, Neoplasms by Site, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Thromboembolism, acquired polycythemia vera, blood coagulation disease, blood platelet disease, bone marrow disorder, bone marrow neoplasm, cardiovascular disorder, cellular phase chronic idiopathic myelofibrosis, essential thrombocythemia, hematologic disorder, hematopoietic and lymphoid system neoplasm, hemorrhagic disease, neoplasm, primary myelofibrosis, thrombocytosis disease, vascular disorder, venous thromboembolism | Recruiting | Phase 3 | 2026-03-20 | NCT05198960 | |
| Interest of CALR Allele Burden in Diagnosis and Follow-up of Patients With CALR Mutated Myeloproliferative Syndromes (CALRSUIVI) | Hemic and Lymphatic Diseases, Myeloproliferative Disorders, blood coagulation disease, blood platelet disease, bone marrow disorder, cellular phase chronic idiopathic myelofibrosis, essential thrombocythemia, hematologic disorder, hemorrhagic disease, myeloproliferative neoplasm, primary myelofibrosis, thrombocytosis disease | Recruiting | Not applicable | 2026-03-06 | NCT04942080 |